Structure Therapeutics’ (GPCR) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $89.00 price target on the stock.

A number of other analysts have also commented on the company. HC Wainwright decreased their target price on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Monday, May 12th. William Blair began coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. Finally, Citigroup started coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $76.17.

Structure Therapeutics Trading Down 2.6%

GPCR stock opened at $21.79 on Monday. The firm has a market cap of $1.25 billion, a PE ratio of -25.05 and a beta of -1.87. The stock has a 50-day moving average price of $23.46 and a 200-day moving average price of $24.04. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $47.48.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). On average, analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Mariner LLC bought a new stake in Structure Therapeutics in the 4th quarter valued at about $665,000. Invesco Ltd. raised its position in shares of Structure Therapeutics by 4.1% in the fourth quarter. Invesco Ltd. now owns 371,767 shares of the company’s stock valued at $10,082,000 after purchasing an additional 14,559 shares during the period. Barclays PLC lifted its stake in shares of Structure Therapeutics by 42.6% during the 4th quarter. Barclays PLC now owns 115,671 shares of the company’s stock valued at $3,138,000 after buying an additional 34,533 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Structure Therapeutics by 663.8% in the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock worth $152,000 after buying an additional 7,627 shares during the period. Finally, Foresite Capital Management VI LLC bought a new position in Structure Therapeutics in the 4th quarter worth approximately $11,390,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.